IMGN stock forecast
Our latest prediction for ImmunoGen, Inc.'s stock price was made on the June 6, 2018 when the stock price was at 11.39$.
In the short term (2weeks), IMGN's stock price should outperform the market by 0.06%. During that period the price should oscillate between -7.85% and +8.26%.
In the medium term (3months), IMGN's stock price should underperform the market by -0.22%. During that period the price should oscillate between -18.22% and +24.36%.Get email alerts
About ImmunoGen, Inc.
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.
At the moment the company generates 79M USD in revenues.
On its last earning announcement, the company reported a loss of -0.97$ per share.
The book value per share is 0.60$
Three months stock forecastJune 6, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|